8-K
filed February 23, 2023, 6:59 PM ET
ticker BBIO
CIK 0001743881
earnings
confidence high
sentiment neutral
materiality 0.75
BridgeBio Q4 net loss $0.92/sh; cash $466M; board adds McCormick; acoramidis data mid-2023
BridgeBio Pharma, Inc.
2022-FY EPS reported
-$3.26
revenue$77,648,000
- Net loss attributable to common stockholders $137.6M in Q4 ($0.92/sh); full year $481.2M ($3.26/sh).
- Cash, equivalents, marketable securities $466.2M at Dec 31, 2022, down from $787.7M; provides runway into 2024.
- Phase 3 ATTRibute-CM trial of acoramidis for ATTR-CM topline data expected mid-2023.
- Phase 2 PROPEL 2 infigratinib cohort 5 data expected March 2023; Phase 3 initiation planned 2023.
- Board changes: Richard Scheller and Brenton Saunders resigned; Frank McCormick appointed to board.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 1.0
BridgeBio Pharma, Inc. reported financial results for the fourth quarter ended December 31, 2022.
- Period
- the fourth quarter ended December 31, 2022
- Result
- reported results
Exact text from the filing
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today reported its financial results for the fourth quarter and full year ended December 31, 2022 and provided an update on the Company's operations.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 1.0
BridgeBio Pharma, Inc. reported financial results for the full year ended December 31, 2022.
- Period
- the full year ended December 31, 2022
- Result
- reported results
Exact text from the filing
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today reported its financial results for the fourth quarter and full year ended December 31, 2022 and provided an update on the Company's operations.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Richard H. Scheller resigned as Director at BridgeBio Pharma, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On February 21, 2023, Richard H. Scheller, Ph.D. and Brenton L. Saunders each notified BridgeBio Pharma, Inc. (the “Company”), of his decision to resign as a member of the Board of Directors of the Company (the “Board”) effective as of February 21, 2023, and on or about March 6, 2023, respectively.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Brenton L. Saunders resigned as Director at BridgeBio Pharma, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On February 21, 2023, Richard H. Scheller, Ph.D. and Brenton L. Saunders each notified BridgeBio Pharma, Inc. (the “Company”), of his decision to resign as a member of the Board of Directors of the Company (the “Board”) effective as of February 21, 2023, and on or about March 6, 2023, respectively.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Frank McCormick was appointed as Director at BridgeBio Pharma, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
On February 23, 2023, the Company announced that Frank McCormick, Ph.D., F.R.S., D.Sc. (Hon) has been appointed by the Board to serve as a director of the Company and fill the vacancy created by the resignation of Dr. Scheller.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.